Bladder Cancer Market
Global Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (Ivp), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and other) Forecast, 2021-2027 Update Available - Forecast 2024-2030
The global bladder cancer market is growing at a significant CAGR of 5.2% during the forecast period (2021-2027). The market is increasing due to the consumption of tobacco, and smoking, past harmful radiation experiences, parasitic infections, and certain changes in the genes that are linked to bladder cancer. Past treatment with radiation therapy or certain anticancer drugs, such as cyclophosphamide or ifosfamide cause bladder cancer, which are further driving the growth of the market. Additionally, continuous innovation in drug development and technological advancement in different therapies such as immunotherapy and chemotherapy are expected to drive the growth of the global bladder cancer market. The firms present in the market are engrossed in evolving innovative diagnostic and treatment solutions for bladder cancer. For instance, In January 2020, Merck & Co., Inc. received the US FDA approval for pembrolizumab a product that can be used as an alternative to radical surgery in certain bladder cancer patients. Moreover, growing health care expenditures are likely to drive the bladder cancer market across the globe. However, the increase in the number of drug patent terminations, the rise in the use of generic drugs, the asymptomatic nature of the disease, the high costs of therapies, and inaccurate and unaffordable diagnosis are the restraining factors of the global market.
Impact of COVID-19 on the Bladder Cancer Market
The global bladder cancer market significantly affected by the COVID-19 pandemic since December 2019, The COVID-19 pandemic has increased by waiting times for cystoscopies and raise concerns of deferred diagnoses and inferior surveillance of bladder cancer. To overcome this pandemic the company’s expanding the role of urinary biomarkers in diagnostic and surveillance pathways could be a strategy to address this problem.
Segmental Outlook
The market is segmented based on cancer type, diagnosis method, and therapy. Based on cancer type, the market is segmented into transitional cell bladder cancer/urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, other rare types (sarcomas, carcinoma in situ). By diagnosis method, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on therapy, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, others.
Global Bladder Cancer Market Share by Cancer type, 2020 (%)
The transitional cell bladder cancer segment projected to dominate the global bladder cancer market
Among cancer types, the transitional cell bladder cancer/ urothelial carcinoma segment holds the largest market share in the global bladder cancer market. The growth of the segment is attributed to the fact that transitional cell bladder cancer/urothelial carcinoma is the most common type of bladder cancer having more prevalence than any other type of bladder cancer. Urothelial carcinoma is a malignant neoplasm happening from the urothelium. The syndrome is one of the ninth most common malignancies across the globe, with around 2.5 million patients, and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) accounted for about 90% of all urinary cancer cases.
Regional Outlook
The global bladder cancer market is analyzed on the basis of the geographical regions that are contributing significantly to the growth of the market. The market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific) and Rest of the World (RoW). North America is estimated to contribute a significant share in the global bladder cancer market. The growth of the region is attributed to high healthcare expenditure, increasing prevalence of bladder cancer coupled with the surging geriatric population, and the presence of major market players in the region.
Global Bladder Cancer Market Growth by Region, 2020-2027
Market Players Outlook
Further, the report covers the analysis of various players operating in the global bladder cancer market, Some of the major players covered in the report include Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Bristol-Myers Squibb Co., AstraZeneca Plc, Merck KGaA, and others. To sustain a strong position in the market, these players adopt different marketing strategies such as a merger, acquisitions, product launches, and geographical expansion. For instance, In September 2020, Bristol-Myers Squibb received the US FDA Approval for Opdivo (nivolumab) in Previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. In April 2020, Merck KGaA, and Pfizer Inc. the biopharmaceutical company received the US (FDA) Food and Drug Administration approval for BAVENCIO. That can be used for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global bladder cancer market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Regulations
3. Competitive Landscape
Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Bladder Cancer Market, By Cancer Type
5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma
5.1.2. Squamous Cell Bladder Cancer
5.1.3. Adenocarcinoma
5.1.4. Other Rare Types (Sarcomas, Carcinoma in Situ)
5.2. Global Bladder Cancer Market, By Diagnosis Method
5.2.1. Cystoscopy
5.2.2. Biopsy
5.2.3. Urinalysis
5.2.4. Urine Cytology
5.2.5. Intravenous Pyelogram (IVP)
5.2.6. Other
5.3. Global Bladder Cancer Market, By Therapy
5.3.1. Chemotherapy
5.3.2. Immunotherapy
5.3.3. Radiation Therapy
5.3.4. Surgery
5.3.5. Other
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profile
7.1. AstraZeneca PLC
7.2. Bristol-Myers Squibb Co.
7.3. Celgene Corp.
7.4. Eli Lilly And Co.
7.5. Endo International Plc
7.6. Epocrates, Inc.
7.7. GlaxoSmithKline Plc
7.8. Hoffmann-La Roche Ltd.
7.9. Johnson & Johnson Services, Inc.
7.10. Merck & Co., Inc.
7.11. Merck KGaA
7.12. Novartis International AG
7.13. Nucleix Ltd.
7.14. Pfizer Inc.
7.15. Spectrum Pharmaceuticals, Inc.
1. GLOBAL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE 2020-2027 ($ MILLION)
2. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
3. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
4. GLOBAL SQUAMOUS CELL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
5. GLOBAL ADENOCARCINOMA MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
6. GLOBAL OTHER RARE TYPES (SARCOMAS, CARCINOMA IN SITU) MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
7. GLOBAL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2020-2027 ($ MILLION)
8. GLOBAL CYSTOSCOPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
9. GLOBAL BIOPSY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
10. GLOBAL URINALYSIS FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
11. GLOBAL URINE CYTOLOGY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
12. GLOBAL INTRAVENOUS PYELOGRAM (IVP) FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
13. GLOBAL OTHER DIAGNOSIS METHOD FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
14. GLOBAL BLADDER CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY 2020-2027 ($ MILLION)
15. GLOBAL CHEMOTHERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
16. GLOBAL IMMUNOTHERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
17. GLOBAL RADIATION THERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
18. GLOBAL SURGERY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
19. GLOBAL OTHER THERAPY FOR BLADDER CANCER MARKET RESEARCH AND ANALYSIS, 2020-2026 ($ MILLION)
20. NORTH AMERICA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)
21. NORTH AMERICA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)
22. NORTH AMERICA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)
23. EUROPE BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)
24. EUROPE BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)
25. EUROPE BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)
26. ASIA-PACIFIC BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)
27. ASIA-PACIFIC BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)
28. ASIA-PACIFIC BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)
29. REST OF THE WORLD BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2020-2027 ($MILLION)
30. REST OF THE WORLD BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD TYPE, 2020-2027 ($MILLION)
31. REST OF THE WORLD BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2020-2027 ($MILLION)
1. IMPACT OF COVID-19 ON GLOBAL BLADDER CANCER MARKET, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL BLADDER CANCER MARKET BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL BLADDER CANCER MARKET, 2021-2027 (%)
4. GLOBAL BLADDER CANCER MARKET BY CANCER TYPE, 2020 VS 2027 (%)
5. GLOBAL BLADDER CANCER MARKET BY DIAGNOSIS METHOD, 2020 VS 2027 (%)
6. GLOBAL BLADDER CANCER MARKET BY THERAPY TYPE, 2020 VS 2027 (%)
7. GLOBAL BLADDER CANCER MARKET BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET SHARE BY REGION, 2020 VS 2026 (%)
9. GLOBAL TRANSITIONAL CELL BLADDER CANCER/ UROTHELIAL CARCINOMA MARKET SHARE BY REGION, 2020 VS 2026 (%)
10. GLOBAL SQUAMOUS CELL BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
11. GLOBAL ADENOCARCINOMA MARKET SHARE BY REGION, 2020 VS 2026 (%)
12. GLOBAL OTHER RARE TYPES (SARCOMAS, CARCINOMA IN SITU) MARKET SHARE BY REGION, 2020 VS 2026 (%)
13. GLOBAL CYSTOSCOPY FOR BLADDER CANCERMARKET SHARE BY REGION, 2020 VS 2026 (%)
14. GLOBAL BIOPSY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
15. GLOBAL URINALYSIS FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
16. GLOBAL URINE CYTOLOGY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
17. GLOBAL INTRAVENOUS PYELOGRAM (IVP) FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
18. GLOBAL OTHER DIAGNOSIS METHOD FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
19. GLOBAL CHEMOTHERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
20. GLOBAL IMMUNOTHERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
21. GLOBAL RADIATION THERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
22. GLOBAL SURGERY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
23. GLOBAL OTHER THERAPY FOR BLADDER CANCER MARKET SHARE BY REGION, 2020 VS 2026 (%)
24. US BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
25. CANADA BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
26. UK BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
27. GERMANY BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
28. SPAIN BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
29. FRANCE BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
30. TALY BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
31. REST OF EUROPE BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
32. INDIA BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
33. CHINA BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
34. JAPAN BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
35. REST OF ASIA-PACIFIC BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
36. REST OF THE WORLD BLADDER CANCER MARKET SIZE, 2020-2027 ($ MILLION)
